raltegravir (Isentress)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Charles Patrick Davis, MD, PhD
    Charles Patrick Davis, MD, PhD

    Charles Patrick Davis, MD, PhD

    Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.

HIV/AIDS Myths and Facts

PREPARATIONS:

  • Film coated oral tablets: 400 mg
  • Chewable oral tablets: 25 mg and 100 mg
  • Granules for oral suspension: single use packet of 100 mg

DRUG INTERACTIONS:

  • Raltegravir is primarily broken down by UGT1A1 enzymes. Medicines which alter the activity of these enzymes may affect blood levels of raltegravir. For example, rifampin (Rimactane) is known to increase the activity of UGT1A1 enzymes, and consequently reduces the blood levels of raltegravir.
  • Patients should avoid taking raltegravir with aluminum or magnesium containing antacids which may reduce blood levels of raltegravir.

PREGNANCY AND BREASTFEEDING SAFETY:

  • Use of raltegravir in pregnant women has not been adequately evaluated. Due to the lack of conclusive safety data, raltegravir should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Raltegravir is classified as FDA pregnancy risk category C.
  • Breastfeeding is not recommended while taking raltegravir. To avoid transmitting the HIV-1 virus to the nursing infant, it is not recommended that HIV-1-infected mothers breastfeed their infants. It is not known if raltegravir is excreted into human milk.

STORAGE:

  • Raltegravir should be stored at room temperature between 20 C to 25 C (68 F to 77 F).
  • For best protection the chewable tablets and granules for oral suspension should be stored in the original container.
Medically Reviewed by a Doctor on 6/24/2016

Quick GuideHIV AIDS Pictures Slideshow: Myths and Facts on Symptoms and Treatments

HIV AIDS Pictures Slideshow: Myths and Facts on Symptoms and Treatments
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: raltegravir on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors